PharmaResearch Co. Ltd.

Kim Kardashian recently tried a new beauty treatment, the salmon-sperm facial (also known as the Rejuran Skin Booster). The Rejuran Healing Essence (Rejuran for Mesotherapy) is being successfully marketed in the United States. https://lnkd.in/gUVi_U5q

Exciting Launch of Rejuran HB Plus in Singapore! We are thrilled to announce the successful launch symposium of Rejuran HB Plus, held earlier this month at the Four Seasons Hotel in Singapore. This symposium was dedicated to sharing the advanced technology and clinical experiences of Rejuran HB Plus with local aesthetic experts and medical professionals. Key opinion leader (KOL) Dr. Michael J. Kim moderated the event, with distinguished speakers including Dr. Hoseong Choi from Korea, and local medical experts Dr. Shenthilkumar Naidu and Dr. Ngiam Juzheng. Dr. Hoseong Choi introduced various procedures using DOT (DNA Optimizing Technology) and Rejuran HB Plus. DOT is PharmaResearch’s patented technology that optimizes DNA extracted from salmon for human use. Rejuran HB Plus incorporates DOT PN (Polynucleotide) to deliver remarkable results. Following this, Dr. Shenthilkumar Naidu and Dr. Ngiam Juzheng shared their clinical experiences and the effectiveness of Rejuran HB Plus. A PharmaResearch representative stated, "This symposium highlighted the distinctive clinical strengths and superior efficacy of Rejuran HB Plus to the Singapore medical community. Building on the successful Singapore launch, we are committed to introducing competitive aesthetic solutions to the global market." Rejuran HB Plus is a skin booster that combines the main ingredient of Rejuran, PN (Polynucleotide), with the moisturizing component HA (Hyaluronic Acid). Stay tuned for more updates as we continue to expand our presence globally! #PharmaResearch #RejuranHBPlus #Aesthetics #MedicalInnovation #GlobalLaunch #ClinicalExcellence https://lnkd.in/gH3miq8x

PharmaResearch Achieves Milestone with PN Medical Device 'Rejuran' We are thrilled to announce that PharmaResearch has surpassed the cumulative sales of 10 million cc for our PN medical device 'Rejuran' earlier this month. Rejuran, designed for facial wrinkle improvement, employs PharmaResearch's proprietary DOT (DNA Optimizing Technology) PN (Polynucleotide). Since its launch in 2014, over 500,000 people have benefited from its unique formula each year. This marks a significant achievement as the first product of its kind among PN component skin boosters. Building on its solid foundation in the domestic market, Rejuran is making substantial strides globally. With product registration and sales in over 30 countries across Asia, North America, Europe, and the Middle East, our export growth has averaged over 51% annually since 2019. A representative from PharmaResearch stated, "The achievement of 10 million cc cumulative sales for Rejuran reflects its superior efficacy and high safety profile. We will continue to align with the K-beauty trend and implement diverse marketing strategies to enable consumers worldwide to experience Rejuran." #PharmaResearch #Rejuran #KBeauty #Milestone #GlobalExpansion #SkincareInnovation #DOTTechnology #Polynucleotide #MedicalDevices https://lnkd.in/gwHKVaph

PharmaResearch Donates Medical Supplies Worth KRW 160 Million to National Team Training Center   [DailyPharm=Reporter Seokjun Lee] PharmaResearch (CEO Ki-Seock Kang, CEO Thinkyou Kim), a company specializing in regenerative medicine, announced on the 1st that it held a donation ceremony for medical supplies worth KRW 160 million to support the national athletes training for the Paris Olympics at the Jincheon National Training Center. The ceremony was attended by Jae-geun Jang, Director of the National Training Center, Thinkyou Kim, CEO of PharmaResearch, and other officials. PharmaResearch donated items including 'Condrotide®', 'Conjuran®', 'Placentex Injection®', 'Re-ahn® Eye Drops', 'Rejuderma®', 'Conjurex Gel', and 'Biome Healer Sunscreen', totaling KRW 160 million in pharmaceuticals, medical devices, and cosmetics.   Director Jae-geun Jang expressed his gratitude, saying, "We thank PharmaResearch for donating various products to support the athletes preparing for the Paris Olympics. The Training Center will do its best in various ways to ensure that the athletes can compete in optimal condition." Thinkyou Kim, CEO of PharmaResearch, stated, "We hope that the donated items will help the national athletes recover safely and quickly from injuries and maintain their best condition." PharmaResearch is a regenerative medicine-based pharmaceutical and biotech company that manufactures and sells pharmaceuticals, medical devices, cosmetics, and health supplements, focusing on tissue regeneration substances such as DOT®PDRN and DOT®PN. Its leading products include Rejuran®, Conjuran®, Rejuran Cosmetics, and Re-Ahn® Eye Drops. https://lnkd.in/gyarcWZ6

PharmaResearch Opens In-House Library PharmaResearch, a company specializing in regenerative medicine, has opened its in-house library. PharmaResearch announced on the 27th that it held an opening ceremony for its employee-created in-house library, "PADO," at its Pangyo headquarters. "PADO," meaning "Finding new paths in the endless waves of knowledge," was an idea proposed by employees and transformed unused space in the office building into a cultural space. At the opening ceremony, cultural journalist and author So-Young Moon gave a book talk. She expressed her support and encouragement for the employees' voluntary efforts toward intellectual growth and cultural enrichment. The PADO library houses approximately 2,000 books spanning various genres, from humanities to natural sciences and comics. PharmaResearch plans to host a variety of cultural events reflecting employees' interests, including book talks, reading discussion groups, and sessions that combine film and literature. A PharmaResearch representative said, "This library's establishment is significant as it was realized through the voluntary participation of PharmaResearch and PharmaResearch Cultural Foundation employees. We will continue to discuss and incorporate various ideas to create a better company with our employees." https://lnkd.in/ggCR_Eju

PharmaResearch Bio Secures Patent for Calcium Filler Composition PharmaResearch Bio, a subsidiary of PharmaResearch specializing in the toxin segment (CEOs Seung-Geol Baek and Chi-Yeop Won), announced on the 10th that it has obtained a patent for the "Filler Composition Containing Nucleic Acid and Calcium Hydroxylapatite." This composition, commonly referred to as the "Calcium Filler," combines calcium hydroxylapatite (CaHAp) with nucleic acid, a DNA mixture extracted from fish. This innovative formula enhances biocompatibility, volume effect, and durability. With this patent, PharmaResearch Bio expands its business scope beyond the existing botulinum toxin to include calcium fillers. A representative from PharmaResearch Bio stated, "We anticipate synergistic effects with our existing botox business through this patent acquisition. We will continue to expand our portfolio to meet various needs in the aesthetic market." PharmaResearch Bio currently produces and exports botulinum toxin products, ReNTox Injection 100 units and 200 units, and received domestic approval for Lientox Injection 100 units last February.

Pharmaresearch Hosts ART Symposium to Showcase Aesthetic Products Centered on Rejuran Pharmaresearch held the 'ART Symposium' at the Grand Walkerhill Hotel from June 1-2, focusing on introducing their aesthetic product line centered around Rejuran. The symposium, attended by over 80 aesthetic medical professionals, served as a platform for sharing clinical data and insights on beauty medical trends. Notable presentations included: - Dr. Hyun Joon Park and Dr. Soo Yeon Park discussing advanced Rejuran techniques and ingredient differentiation. - Dr. Seung Min Oh presenting clinical results of using Rejuviel for eye fillers. - Dr. Dong Hwan Kim introducing 'JBP Plamonju,' a menopausal treatment using Japanese placenta-based ingredients. - Dr. Jae Wan Hwang and Dr. Seung Hyun Lee sharing real-life cases and the effectiveness of Rejuran and Rejuderma, highlighting Rejuran's competitiveness in the global market. Pharmaresearch emphasized the safety and scientific basis of their aesthetic products and plans to continue creating opportunities for medical professionals to share their expertise. Pharmaresearch specializes in regenerative medicine products, including DOT®PDRN and DOT®PN, and manufactures pharmaceuticals, medical devices, cosmetics, and health supplements. Key products include Rejuran®, Rejuviel®, Conjuran®, JBP Plamonju, Rejuran® Cosmetic, Lian® Eye Drops, and Rejuderma®. https://lnkd.in/gCTsb_u9

PharmaResearch Signs Strategic Agreement with DOF to Develop Injectable Using Supercritical Carbon Dioxide Decellularization Technology. PharmaResearch, a company specializing in regenerative medicine, announced on the 30th that it signed a strategic mutual cooperation agreement with DOF, a biomedical company, on the 29th to develop an injectable product using Human Acellular Dermal Matrix (HADM) as the main ingredient. DOF is a bio-company that has successfully commercialized human tissue grafts by applying the world's first "supercritical carbon dioxide decellularization technology." This technology, essential for preparing human tissues for transplantation, replaces traditional chemical substances like surfactants with carbon dioxide, making it an eco-friendly process. Notably, compared to surfactant-based decellularization methods, this technology maintains higher levels of extracellular matrix (ECM) and various growth factors. Through this agreement, PharmaResearch plans to launch 'SCecm L,' a regenerative injectable product utilizing the 'supercritical carbon dioxide decellularization technology,' within this year. A representative from PharmaResearch stated, "We decided on a strategic partnership with DOF to accelerate innovation in the field of regenerative medicine," adding that both companies will strengthen cooperation to ensure the launch and commercialization of SCecm L within the year. 파마리서치, 생체재료 전문 기업 도프와 상호협력 계약 (mtn.co.kr)

New PharmaResearch Company Deck https://lnkd.in/gtmDX8t2